DelveInsight Report: Over 12 Companies Enter iPSC-Derived NK Cell Therapy Pipeline, Led by Century Therapeutics and Fate Therapeutics

August 23, 2026

openPR.com (DelveInsight) India

Overview

This article provides an overview of a market research report published by DelveInsight, highlighting the rapid growth in the iPSC-derived NK cell therapy pipeline, with over 12 companies developing more than 15 drug candidates. Century Therapeutics’ CNTY-101, a CD19-targeted CAR-NK cell, is in Phase I/II for autoimmune diseases, while Fate Therapeutics’ FT522, an iPSC-derived CAR-NK cell, is in Phase I for relapsed/refractory B-cell lymphoma. These therapies are poised to become next-generation cancer immunotherapies due to their potential for standardized mass production.

In Depth

This article is an overview of a market research report published by DelveInsight.

Report Overview

According to a recent report by DelveInsight, the market for iPSC (induced pluripotent stem cell)-derived Natural Killer (NK) cell therapies is experiencing rapid development. The report indicates that over 12 companies are currently engaged in developing more than 15 drug candidates, leading to a highly active clinical trial pipeline. The market research focuses on key therapeutics, clinical trial advancements, leading companies, and factors driving market growth.

Key Findings

iPSC-derived NK cell therapies are garnering significant attention as a next-generation cancer immunotherapy due to their pluripotent nature and potential for large-scale, standardized production. Among the leading companies in this pipeline, Century Therapeutics is developing CNTY-101, a CD19-targeted CAR-NK cell therapy, which is currently being evaluated in Phase I/II clinical trials for autoimmune diseases. Another prominent player, Fate Therapeutics, is assessing FT522, an iPSC-derived CAR-NK cell therapy, in Phase I clinical trials for relapsed/refractory B-cell lymphoma. These iPSC-derived NK cells demonstrate high cellular activity and favorable safety profiles, promising to overcome manufacturing challenges associated with existing cell therapies and offer accessible treatments to a broader patient population.

About the Publisher

DelveInsight is a specialized market research and consulting firm dedicated to the life sciences sector. The company provides in-depth market analysis reports across a wide range of areas, including pharmaceuticals, medical devices, and diagnostics. DelveInsight’s insights are crucial for pharmaceutical companies, biotechnology firms, investors, and research institutions in making informed strategic decisions.

Source: https://www.openpr.com/news/4609064/ipsc-derived-nk-cells-clinical-trial-pipeline-analysis-12-key

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.